Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study.

Humans Behcet Syndrome / blood Male Female Adult Biomarkers / blood Retrospective Studies Autoantibodies / blood Middle Aged HLA-B51 Antigen / blood Tumor Necrosis Factor-alpha / blood Young Adult CD4-Positive T-Lymphocytes / immunology Interleukin-4 / blood
Behcet’s syndrome Biomarkers Clinical features Gastrointestinal involvement

Journal

Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405

Informations de publication

Date de publication:
28 Aug 2024
Historique:
received: 28 05 2024
accepted: 05 08 2024
medline: 28 8 2024
pubmed: 28 8 2024
entrez: 28 8 2024
Statut: epublish

Résumé

Behcet's syndrome (BS) is a vasculitis characterized by immune dysregulation. Biomarkers are valuable for assessing clinically atypical pathogenesis. We aimed to investigate the distribution of different biomarkers and their effects on the clinical features of patients with BS in a large-scale, real-world study. This is a retrospective, single-center study. In total, 502 patients diagnosed with BS were enrolled in this study. We analyzed the clinical features of this cohort and divided patients' symptoms into six categories, including mucocutaneous, articular, neurological, gastrointestinal, vascular, and ocular involvements. HLA-B51 cells, autoantibodies, and subsets of immune cells from the patients were tested. Pearson's correlation, Wilcoxon rank sum test and multivariate logistic regression were used for data analysis. Various autoantibodies were detected in the serum of 40.8% of patients with BS. The positivity rate of anti-endothelial cell antibodies (AECA) was the highest among autoantibodies and was found in 23.5% (118/502) of patients with BS. The positivity rate of HLA-B51 in patients with BS was 27.1%. Tumor necrosis factor (TNF)-α, IL-2, and IL-4 producing CD4

Identifiants

DOI: 10.1007/s10238-024-01462-5 PMID: 39196452
pubmed: 39196452
doi: 10.1007/s10238-024-01462-5
pii: 10.1007/s10238-024-01462-5
doi:

Substances chimiques

Biomarkers 0
Autoantibodies 0
HLA-B51 Antigen 0
Tumor Necrosis Factor-alpha 0
anti-endothelial cell antibody 0
Interleukin-4 207137-56-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

201

Informations de copyright

© 2024. The Author(s).

Références

Yazici Y, Hatemi G, Bodaghi B, et al. Behçet syndrome. Nat Rev Dis Primers. 2021;7(1):67. https://doi.org/10.1038/s41572-021-00301-1 .
doi: 10.1038/s41572-021-00301-1 pubmed: 34531393
Bettiol A, Prisco D, Emmi G. Behçet: the syndrome. Rheumatology (Oxford). 2020;59(Suppl 3):iii101–7. https://doi.org/10.1093/rheumatology/kez626 .
doi: 10.1093/rheumatology/kez626 pubmed: 32348523
Takeno M. The association of Behçet’s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol. 2022;34(1):4–9. https://doi.org/10.1097/bor.0000000000000846 .
doi: 10.1097/bor.0000000000000846 pubmed: 34690278
van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behçet’s disease and treatment modalities. Semin Arthritis Rheum. 2022;52: 151956. https://doi.org/10.1016/j.semarthrit.2022.151956 .
doi: 10.1016/j.semarthrit.2022.151956 pubmed: 35038644
Cavers A, Kugler MC, Ozguler Y, et al. Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity. Ann Rheum Dis. 2022;81(11):1603–11. https://doi.org/10.1136/ard-2022-222277 .
doi: 10.1136/ard-2022-222277 pubmed: 35922122
Hatemi G, Seyahi E, Fresko I, et al. Behçet’s syndrome: one year in review 2023. Clin Exp Rheumatol. 2023;41(10):1945–54. https://doi.org/10.55563/clinexprheumatol/7kdo9x .
doi: 10.55563/clinexprheumatol/7kdo9x pubmed: 37877363
Tong B, Liu X, Xiao J, et al. Immunopathogenesis of Behcet’s Disease. Front Immunol. 2019;10:665. https://doi.org/10.3389/fimmu.2019.00665 .
doi: 10.3389/fimmu.2019.00665 pubmed: 30984205 pmcid: 6449449
Legendre P, Régent A, Thiebault M, et al. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev. 2017;16(2):146–53. https://doi.org/10.1016/j.autrev.2016.12.012 .
doi: 10.1016/j.autrev.2016.12.012 pubmed: 27989761
Ooka S, Nakano H, Matsuda T, et al. Proteomic surveillance of autoantigens in patients with Behcet’s disease by a proteomic approach. Microbiol Immunol. 2010;54(6):354–61. https://doi.org/10.1111/j.1348-0421.2010.00215.x .
doi: 10.1111/j.1348-0421.2010.00215.x pubmed: 20536734
Hussain M, Chen P, Zhang Y, et al. Moesin expression is correlated with its involvement in patients with Behcet’s disease. Arch Med Sci. 2020;16(4):924–30. https://doi.org/10.5114/aoms.2020.92911 .
doi: 10.5114/aoms.2020.92911 pubmed: 32542096 pmcid: 7286334
Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565–79. https://doi.org/10.1038/s41584-020-0480-7 .
doi: 10.1038/s41584-020-0480-7 pubmed: 32884126 pmcid: 8456518
Stochmal A, Czuwara J, Trojanowska M, et al. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40–51. https://doi.org/10.1007/s12016-018-8718-8 .
doi: 10.1007/s12016-018-8718-8 pubmed: 30607749
Hernández-Molina G, Nuñez-Alvarez C, Avila-Casado C, et al. Usefulness of IgA Anti-α-fodrin antibodies in combination with rheumatoid factor and/or antinuclear antibodies as substitute immunological criterion in sjögren syndrome with negative anti-SSA/SSB antibodies. J Rheumatol. 2016;43(10):1852–7. https://doi.org/10.3899/jrheum.151315 .
doi: 10.3899/jrheum.151315 pubmed: 27481899
Güngörer V, Polat MC, Çelikel E, et al. Factors associated with the development of thrombosis in pediatric Behçet disease. J Clin Rheumatol. 2023;29(4):e19–24. https://doi.org/10.1097/rhu.0000000000001930 .
doi: 10.1097/rhu.0000000000001930 pubmed: 36473105
Moroi Y, Takeuchi A, Mori M, et al. Antinuclear antibody in Behçet’s disease. J Rheumatol. 1982;9(5):809–10.
pubmed: 6983583
Amin MM, Abdel Latif OM. Anti-tubulin-alpha-1c antibody as a marker of value in Behçet syndrome. Clin Rheumatol. 2022;41(6):1759–67. https://doi.org/10.1007/s10067-021-06025-7 .
doi: 10.1007/s10067-021-06025-7 pubmed: 35128589 pmcid: 9119891
Chiang CP, Wu YH, Chang JY, et al. Hematinic deficiencies and hyperhomocysteinemia in gastric parietal cell antibody-positive or gastric and thyroid autoantibodies-negative Behcet’s disease patients. J Formos Med Assoc. 2019;118(1 Pt 2):347–53. https://doi.org/10.1016/j.jfma.2018.05.017 .
doi: 10.1016/j.jfma.2018.05.017 pubmed: 29898820
Al-Obeidi AF, Nowatzky J. Immunopathogenesis of Behçet’s disease. Clin Immunol. 2023;253: 109661. https://doi.org/10.1016/j.clim.2023.109661 .
doi: 10.1016/j.clim.2023.109661 pubmed: 37295542 pmcid: 10484394
Filleron A, Tran TA, Hubert A, et al. Regulatory T cell/Th17 balance in the pathogenesis of paediatric Behçet disease. Rheumatology (Oxford). 2021;61(1):422–9. https://doi.org/10.1093/rheumatology/keab253 .
doi: 10.1093/rheumatology/keab253 pubmed: 33734346
Le Joncour A, Martos R, Loyau S, et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease. Ann Rheum Dis. 2019;78(9):1274–82. https://doi.org/10.1136/annrheumdis-2018-214335 .
doi: 10.1136/annrheumdis-2018-214335 pubmed: 31147357
The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47. https://doi.org/10.1111/jdv.12107 .
Bhakta BB, Brennan P, James TE, et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38(8):728–33. https://doi.org/10.1093/rheumatology/38.8.728 .
doi: 10.1093/rheumatology/38.8.728 pubmed: 10501420
Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease. Lancet, 1990;335(8697):1078-1080.
Greco A, De Virgilio A, Ralli M, et al. Behçet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–75. https://doi.org/10.1016/j.autrev.2017.12.006 .
doi: 10.1016/j.autrev.2017.12.006 pubmed: 29631062
Bodis G, Toth V, Schwarting A. Role of human leukocyte antigens (HLA) in autoimmune diseases. Methods Mol Biol. 2018;1802:11–29. https://doi.org/10.1007/978-1-4939-8546-3_2 .
doi: 10.1007/978-1-4939-8546-3_2 pubmed: 29858799
Horie Y, Meguro A, Ohta T, et al. HLA-B51 carriers are susceptible to ocular symptoms of Behçet disease and the association between the two becomes stronger towards the east along the silk road: a literature survey. Ocul Immunol Inflamm. 2017;25(1):37–40. https://doi.org/10.3109/09273948.2015.1136422 .
doi: 10.3109/09273948.2015.1136422 pubmed: 26954704
Su G, Zhong Z, Zhou Q, et al. Identification of novel risk Loci for Behçet’s disease-related uveitis in a chinese population in a genome-wide association study. Arthritis Rheumatol. 2022;74(4):671–81. https://doi.org/10.1002/art.41998 .
doi: 10.1002/art.41998 pubmed: 34652073
Hamzaoui A, Houman MH, Massouadia M, et al. Contribution of Hla-B51 in the susceptibility and specific clinical features of Behcet’s disease in Tunisian patients. Eur J Intern Med. 2012;23(4):347–9. https://doi.org/10.1016/j.ejim.2011.12.011 .
doi: 10.1016/j.ejim.2011.12.011 pubmed: 22560383
Karasawa R, Yudoh K, Ozaki S, et al. Anti-endothelial cell antibodies (AECA) in patients with systemic vasculitis: our research using proteomics. Expert Opin Biol Ther. 2011;11(1):77–87. https://doi.org/10.1517/14712598.2011.540234 .
doi: 10.1517/14712598.2011.540234 pubmed: 21133816
Souza RC, Lage L, Goldesntein-Schainberg C, et al. Anti-endothelial cell antibodies and central nervous system involvement in Behçet’s disease. Clinics (Sao Paulo). 2007;62(6):685–90. https://doi.org/10.1590/s1807-59322007000600005 .
doi: 10.1590/s1807-59322007000600005 pubmed: 18209908
Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet’s disease: a review. World J Gastroenterol. 2015;21(13):3801–12. https://doi.org/10.3748/wjg.v21.i13.3801 .
doi: 10.3748/wjg.v21.i13.3801 pubmed: 25852265 pmcid: 4385527
He K, Wu D. The treatment principles and targets for intestinal Behcet’s disease. Therap Adv Gastroenterol. 2023;16:17562848231167284. https://doi.org/10.1177/17562848231167283 .
doi: 10.1177/17562848231167283 pubmed: 37113192 pmcid: 10126606
Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22052719 .
doi: 10.3390/ijms22052719 pubmed: 35008852 pmcid: 8745242
Zhang M, Liu J, Liu T, et al. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet’s disease, a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(4):608–19. https://doi.org/10.1111/jgh.15754 .
doi: 10.1111/jgh.15754 pubmed: 34894004
Novak T, Hamedi M, Bergmeier LA, et al. Saliva and serum cytokine profiles during oral ulceration in Behçet’s disease. Front Immunol. 2021;12: 724900. https://doi.org/10.3389/fimmu.2021.724900 .
doi: 10.3389/fimmu.2021.724900 pubmed: 35003055 pmcid: 8727526
Akkurt ZM, Bozkurt M, Uçmak D, et al. Serum cytokine levels in Behçet’s disease. J Clin Lab Anal. 2015;29(4):317–20. https://doi.org/10.1002/jcla.21772 .
doi: 10.1002/jcla.21772 pubmed: 25130392
Iwaszko M, Biały S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells. 2021. https://doi.org/10.3390/cells10113000 .
doi: 10.3390/cells10113000 pubmed: 34831223 pmcid: 8616130
Nguyen JK, Austin E, Huang A, et al. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312(2):81–92. https://doi.org/10.1007/s00403-019-01972-3 .
doi: 10.1007/s00403-019-01972-3 pubmed: 31493000
Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet’s disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35(6):472–425. https://doi.org/10.1080/03009740600905380 .
doi: 10.1080/03009740600905380 pubmed: 17343257
Cingu AK, Turkcu FM, Aktas S, et al. Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet’s disease. Int Ophthalmol. 2020;40(12):3441–51. https://doi.org/10.1007/s10792-020-01530-1 .
doi: 10.1007/s10792-020-01530-1 pubmed: 32729061
Lin S, Xu Z, Lin Z, et al. Advances in pathogenesis and treatment of ocular involvement in Behcet’s disease. Front Immunol. 2023;14:1206959. https://doi.org/10.3389/fimmu.2023.1206959 .
doi: 10.3389/fimmu.2023.1206959 pubmed: 37841268 pmcid: 10570607

Auteurs

Jiachen Li (J)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Feng Sun (F)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Yingni Li (Y)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Jing Zhao (J)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Rulin Jia (R)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Hongyan Wang (H)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Xiaohong Xiang (X)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Xiaolin Sun (X)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China.

Chengbin Chen (C)

Yulin Red Cross Hospital, Yulin, 537000, Guangxi Zhuang Autonomous Region, China.

Haixin Xu (H)

Beijing Friendship Pinggu Hospital of Capital Medical University, Beijing, 101200, China.

Zhanguo Li (Z)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China. li99@bjmu.edu.cn.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China. li99@bjmu.edu.cn.

Tian Liu (T)

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China. mikle317@163.com.
Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, 100044, China. mikle317@163.com.
Department of Rheumatology and Immunology, Shijiazhuang People's Hospital, Shijiazhuang, 050030, China. mikle317@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Profile of immunological biomarkers in...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses vasculaires › Maladie de Behçet › Profile of immunological biomarkers in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Profile of immunological biomarkers in...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Profile of immunological biomarkers in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Profile of immunological biomarkers in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Profile of immunological biomarkers in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Profile of immunological biomarkers in...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes HLA › Antigènes HLA-B › Antigène HLA-B51 › Profile of immunological biomarkers in...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Profile of immunological biomarkers in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Profile of immunological biomarkers in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Profile of immunological biomarkers in...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-4 › Profile of immunological biomarkers in...